Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship

被引：137

作者：

Ohtani, Naoko ^{[1
]}

Kawada, Norifumi ^{[2
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Dept Pathophysiol, Osaka, Japan

[2] Osaka City Univ, Grad Sch Med, Dept Hepatol, Osaka, Japan

来源：

HEPATOLOGY COMMUNICATIONS | 2019年 / 3卷 / 04期

基金：

日本学术振兴会;

关键词：

PERISINUSOIDAL STELLATE CELLS; PROTON PUMP INHIBITORS; FAT-STORING CELLS; HEPATOCELLULAR-CARCINOMA; BILE-ACIDS; NONALCOHOLIC STEATOHEPATITIS; HEPATIC-ENCEPHALOPATHY; CIRRHOSIS; METABOLISM; MACROPHAGES;

D O I：

10.1002/hep4.1331

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The gut and the liver are anatomically and physiologically connected, and this "gut-liver axis" exerts various influences on liver pathology. The gut microbiota consists of various microorganisms that normally coexist in the human gut and have a role of maintaining the homeostasis of the host. However, once homeostasis is disturbed, metabolites and components derived from the gut microbiota translocate to the liver and induce pathologic effects in the liver. In this review, we introduce and discuss the mechanisms of liver inflammation, fibrosis, and cancer that are influenced by gut microbial components and metabolites; we include recent advances in molecular-based therapeutics and novel mechanistic findings associated with the gut-liver axis and gut microbiota.

引用

页码：456 / 470

页数：15

共 122 条

[1] Current Management of Hepatic Encephalopathy [J].

Acharya, Chathur ;

Bajaj, Jasmohan S. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (11) :1600-1612

[2] An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers [J].

Al-Khaifi, Amani ;

Rudling, Mats ;

Angelin, Bo .

GASTROENTEROLOGY, 2018, 155 (04) :1012-1016

[3] Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non-alcoholic steatohepatitis [J].

Alisi, A. ;

Bedogni, G. ;

Baviera, G. ;

Giorgio, V. ;

Porro, E. ;

Paris, C. ;

Giammaria, P. ;

Reali, L. ;

Anania, F. ;

Nobili, V. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (11) :1276-1285

[4] Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice [J].

Ambade, Aditya ;

Lowe, Patrick ;

Kodys, Karen ;

Catalano, Donna ;

Gyongyosi, Benedek ;

Cho, Yeonhee ;

Iracheta-Vellve, Arvin ;

Adejumo, Adeyinka ;

Saha, Banishree ;

Calenda, Charles ;

Mehta, Jeeval ;

Lefebvre, Eric ;

Vig, Pamela ;

Szabo, Gyongyi .

HEPATOLOGY, 2019, 69 (03) :1105-1121

[5] NASH-Related Cirrhosis: An Occult Liver Disease Burden [J].

Arrese, Marco ;

Feldstein, Ariel E. .

HEPATOLOGY COMMUNICATIONS, 2017, 1 (02) :84-86

[6] Decompensated cirrhosis and microbiome interpretation [J].

Bajaj, Jasmohan S. ;

Betrapally, Naga S. ;

Gillevet, Patrick M. .

NATURE, 2015, 525 (7569) :E1-E2

[7] Current and future pharmacologic treatment of nonalcoholic steatohepatitis [J].

Banini, Bubu A. ;

Sanyal, Arun J. .

CURRENT OPINION IN GASTROENTEROLOGY, 2017, 33 (03) :134-141

[8] Global trends and predictions in hepatocellular carcinoma mortality [J].

Bertuccio, Paola ;

Turati, Federica ;

Carioli, Greta ;

Rodriguez, Teresa ;

La Vecchia, Carlo ;

Malvezzi, Matteo ;

Negri, Eva .

JOURNAL OF HEPATOLOGY, 2017, 67 (02) :302-309

[9] PERISINUSOIDAL STELLATE CELLS OF THE LIVER - IMPORTANT ROLES IN RETINOL METABOLISM AND FIBROSIS [J].

BLOMHOFF, R ;

WAKE, K .

FASEB JOURNAL, 1991, 5 (03) :271-277

[10] Gut microbiota and diabetes: from pathogenesis to therapeutic perspective [J].

Burcelin, Remy ;

Serino, Matteo ;

Chabo, Chantal ;

Blasco-Baque, Vincent ;

Amar, Jacques .

ACTA DIABETOLOGICA, 2011, 48 (04) :257-273

← 1 2 3 4 5 6 7 8 9 10 →